Entering text into the input field will update the search result below

BioNTech, Regeneron add lung cancer for studies on mRNA-based shot and Libtayo

Mar. 08, 2022 8:50 AM ETBioNTech SE (BNTX), REGN, SNYPFEBy: Dulan Lokuwithana, SA News Editor

Gratitude Concept With Heart Symbol

Eoneren/E+ via Getty Images

  • On Tuesday, German vaccine maker BioNTech (NASDAQ:BNTX) announced an expansion of its strategic collaboration with Regeneron (NASDAQ:REGN) to add advanced non-small cell lung cancer (NSCLC) for combination studies involving its mRNA-based cancer shot BNT116 and Libtayo.

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.